{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:31:27Z","timestamp":1740130287678,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS","doi-asserted-by":"publisher","award":["16H05389"],"award-info":[{"award-number":["16H05389"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To explore radiation oncologists\u2019 attitudes and practice patterns of radiotherapy for hormone-na\u00efve prostate cancer with bone metastases in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An internet-based survey was distributed to board-certified radiation oncologists of the Japanese Society of Radiation Oncology. Three hypothetical cases were assumed: hormone-na\u00efve prostate cancer with single, three or multiple non-symptomatic bone metastases. The respondents described their attitude regarding such cases, treatment methods and the radiotherapy dose fractionation that they would recommend.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the 1013 board-certified radiation oncologists in Japan, 373 (36.8%) responded to the questionnaire. Most of the respondents (85.0%) believed that radiotherapy may be applicable as a primary treatment for hormone-na\u00efve prostate cancer with bone metastases in some circumstances. For Case 1 (single bone metastasis), 55.0% of the respondents recommended radiotherapy for the prostate and bone metastasis. For Case 2 (three bone metastases), only 24.4% recommended radiotherapy for all lesions, and 31.4% recommended radiotherapy for the prostate only. For Case 3 (multiple bone metastases), 49.1% of the respondents stated that there was no indication for radiotherapy. However, 34% of the respondents still preferred to administer radiotherapy for the prostate. The radiotherapy techniques and dose fractionations varied widely among the respondents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Most of the respondent radiation oncologists believed that radiotherapy may be beneficial for hormone-na\u00efve prostate cancer with bone metastases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa111","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T11:30:56Z","timestamp":1591788656000},"page":"1188-1194","source":"Crossref","is-referenced-by-count":2,"title":["National survey of radiation oncologists\u2019 practice patterns regarding hormone-na\u00efve prostate cancer with bone metastases"],"prefix":"10.1093","volume":"50","author":[{"given":"Katsumasa","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"National Institutes for Quantum and Radiological Science and Technology, Hospital of the National Institute of Radiological Science, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kariya","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kochi Medical School, Nankoku, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemasa","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Kumano","sequence":"additional","affiliation":[{"name":"Department of Radiology, Gifu University of Medical Science, Graduate School of Medicine, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuyo","family":"Kozuka","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Toranomon Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakuni","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nihon University School of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Tenri Yorozu Hospital, Tenri, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Other authors are shown in Appendix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"2020092802445219500_ref1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"2020092802445219500_ref2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12885-017-3455-6","article-title":"A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)","volume":"17","author":"Radwan","year":"2017","journal-title":"BMC Cancer"},{"key":"2020092802445219500_ref3","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J Clin Oncol"},{"key":"2020092802445219500_ref4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","article-title":"Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis","volume":"194","author":"Satkunasivam","year":"2015","journal-title":"J Urol"},{"key":"2020092802445219500_ref5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"2020092802445219500_ref6","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"2020092802445219500_ref7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"2020092802445219500_ref8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-019-0791-5","article-title":"Trends in management of oligometastatic hormone-sensitive prostate cancer","volume":"21","author":"Kothari","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"2020092802445219500_ref9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"key":"2020092802445219500_ref10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.prnil.2017.04.003","article-title":"Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer","volume":"5","author":"Sinha","year":"2017","journal-title":"Prostate Int"},{"author":"ClinicalTrials.gov","key":"2020092802445219500_ref11"},{"author":"National Comprehensive Cancer Network","key":"2020092802445219500_ref12"},{"key":"2020092802445219500_ref13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020092802445219500_ref14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"2020092802445219500_ref15","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of 68Ga-PSMA-11 PET\/CT on the planning of definitive radiation therapy for prostate cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"2020092802445219500_ref16","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2016.03.021","article-title":"Ten-and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7","volume":"70","author":"Foss\u00e5","year":"2016","journal-title":"Eur Urol"},{"key":"2020092802445219500_ref17","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"2020092802445219500_ref18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/pros.23757","article-title":"Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: a retrospective cohort study","volume":"79","author":"Tsumura","year":"2019","journal-title":"Prostate"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/10\/1188\/33797091\/hyaa111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/10\/1188\/33797091\/hyaa111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T06:45:10Z","timestamp":1601275510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/10\/1188\/5867188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,7,6]]},"published-print":{"date-parts":[[2020,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa111","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,7,6]]}}}